



BILASTINE IS APPROVED IN EIGHT EUROPEAN COUNTRIES

Approvals continue in new European countries.

Germany, Denmark, Bulgaria and Sweden have also approved Bilastine's commercialization.

So, adding Spain, United Kingdom, Island and Portugal there are already eight European countries that have approved Bilastine's commercialization.

During next months, we expect to complete the rest of approvals in European countries, up to a total of 29. Bilastine will, therefore, be available for most European patients along 2011.

Bilastine is a latest generation antihistaminic, with a rapid onset and long lasting action, showing a wide safety profile, indicated for the treatment of allergic rhinoconjunctivitis and urticary.